Do sex and ethnicity influence drug pharmacokinetics in solid organ transplantation?

Graft

Volumn 5, Issue 5, 2002, Pages 294-302

  Scott Mathis, A ^a   Friedman, Gary S ^a   Knipp, Gregory T ^a  

^a SAINT BARNABAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450 3A; CYTOCHROME P450 3A5; CYTOKINE; DRUG METABOLIZING ENZYME; EVEROLIMUS; FLUCONAZOLE; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; KETOCONAZOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; STEROID; TACROLIMUS;

AREA UNDER THE CURVE; CAUCASIAN; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG RESPONSE; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; ETHNOLOGY; FEMALE; GENETIC REGULATION; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; MENSTRUAL CYCLE; NEGRO; ORGAN TRANSPLANTATION; PHARMACODYNAMICS; REVIEW; SEX DIFFERENCE;

EID: 0036342061     PISSN: 15221628     EISSN: None     Source Type: Journal    
DOI: 10.1177/1522162802005005003     Document Type: Review

References (60)

1. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability
2. Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics
3. Methylprednisolone pharmacokinetics, cortisol response, and adrenal effects in black and white renal transplant recipients
4. Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race
5. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine
6. The adverse impact of high cyclosporine. Clearance rates on the incidences of acute rejection and graft loss
7. Demographic considerations in tacrolimus pharmacokinetics
8. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestines
9. Gender-dependent racial difference in disposition of cyclosporine among healthy African-American and white volunteers
10. The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups
11. Cyclosporine pharmacokinetics and pharmacodynamics in African-Americans and white subjects
12. Impact of sirolimus on renal transplant outcomes in African-Americans
13. Mycophenolic acid area under the curve values in African-American and Caucasian renal transplant patients are comparable
14. In vivo higher glucuronidation of mycophenolic acid in male than female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil
15. Population pharmacokinetics of everolimus in de novo renal transplant patients: Impact of ethnicity and comedications
16. Racial profiling in medical research
17. Racial differences in the response to drugs-pointers to genetic differences
18. Ethnicity as a variable in epidemiologic research
19. African-American renal transplant recipients experience decreased risk of death due to infection: Possible implications for immunosuppressive strategies
20. Ethnic differences in clinical response to corticosteroid treatment of acute renal allograft rejection
21. Is it sex or is it gender?
22. Drug interactions involving immunosuppressive agents
23. The effect of gender on ketoconazole induced changes in tacrolimus pharmacokinetics
24. Sex and ethnicity may chiefly influence the interaction of fluconazole with calcineurin inhibitors
25. Effect of grapefruit juice on pharmacokinetics of microemulsion cyclosporine in African-American subjects compared with Caucasian subjects: Does ethnic difference matter?
26. Gender effects in pharmacokinetics and pharmacodynamics
27. Predictability of the effects of race or ethnicity on pharmacokinetics of drugs
28. Molecular basis of ethnic differences in drug disposition and response
29. Pharmacogenomics: Translating functional genomics into rational therapeutics
30. First-pass metabolism of cyclosporine by the gut
31. Drug metabolism by cytochromes P450 in the liver and small bowel
32. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine
33. Effects of age and gender on in vitro properties of human liver microsomal preparations
34. CYP3A activity in African-American and European American men: Population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphism
35. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
36. CYP3A4*1B as a pharmacogenomic predictor of low tacrolimus requirements in liver transplant patients
37. Pharmacogenomic effects of a polymorphism in the 5′ promoter region of CYP3A4 in stable kidney transplant recipients
38. Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe
39. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
40. Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient. Possible relationship to intestinal P-glycoprotein activity
41. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
42. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation
43. Correlation of gene expression on ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers
44. The expression of nine multiple drug resistance conferring proteins in the Chinese and Caucasian small and large intestines
45. Polymorphism of the ABC transporter genes, MDR1, MRP1, and MRP2/cMOAT, in healthy Japanese subjects
46. Frequency of C3435T polymorphism of MDR1 gene in African people
47. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
48. The relationship of P-glycoprotein genotypes and cyclosporine pharmacokinetic parameters among healthy individuals
49. Membrane transport of mycophenolate mofetil and its active metabolite, mycophenolic acid in MDCK and MDR1-MDCK cell monolayers
50. P-glycoprotein expression in patients before and after kidney transplantation
51. Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture
52. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients
53. 6′,7′- Dihydroxybergamottin in grapefruit juice and Seville orange juice: Effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein
54. The influence of pineapple and onion on the absorption of cyclosporine in animal study
55. TNF-α, IFN-γ, IL-6, IL-10, and TGF-β1 gene polymorphisms in renal allografts
56. Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6
57. Drug-cytokine interactions: Focus on cyclosporine
58. Gender-based differences and menstrual cycle-related changes in specific diseases: Implications for pharmacotherapy
59. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam
60. Pharmacogenomics: A clinician's primer on emerging technologies for improved patient care